3/3-Exposure D-Cycloserine Enhancement and Genetic Modulators in Panic Disorder
恐慌症中的 3/3 暴露 D-环丝氨酸增强剂和遗传调节剂
基本信息
- 批准号:7795799
- 负责人:
- 金额:$ 23.9万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2008
- 资助国家:美国
- 起止时间:2008-04-24 至 2013-03-31
- 项目状态:已结题
- 来源:
- 关键词:Acquired Immunodeficiency SyndromeAcuteAddressAdherenceAdultAdverse eventAftercareAgonistAgoraphobiaAmygdaloid structureAnxietyAnxiety DisordersAreaBasic ScienceBehavior TherapyBehavioral SciencesBindingBostonBrain-Derived Neurotrophic FactorBudgetsCensusesChairpersonCitiesClinicalClinical ResearchClinical ServicesClinical Trials Data Monitoring CommitteesCognitive TherapyCollaborationsCombined Modality TherapyCommunicationComplementCountryCountyCultural DiversityCycloserineDataData AnalysesData CollectionDoctor of MedicineDoctor of PhilosophyDoseDouble-Blind MethodEffectivenessEmployee StrikesEnsureEpidemiologyEvaluationExposure toExtinction (Psychology)FacultyFosteringFrightFunctional disorderFundingFutureGeneral HospitalsGenesGeneticGenetic EnhancementGlutamatesGoalsGrantHealth PrioritiesHeightHospitalsHourHousingImpairmentIndividualInstitutesInterventionInvestigationJordanLaboratory AnimalsLeadLifeLinkLong-Term EffectsMassachusettsMediatingMental HealthMental disordersMinority GroupsN-Methyl-D-Aspartate ReceptorsNTRK2 geneNational Institute of Mental HealthNatureNeurobiologyOutpatientsPanic DisorderParticipantPatientsPatternPharmacotherapyPharmacy facilityPhysiciansPilot ProjectsPlacebosPopulationPrevalenceProceduresProtocols documentationPsychiatric HospitalsPublic HealthPublicationsRandomizedRandomized Controlled TrialsRecording of previous eventsRecruitment ActivityRelative (related person)ReportingResearchResearch DesignResearch Ethics CommitteesResearch PersonnelRoleSafetySamplingSeveritiesSiteStructureSubgroupSymptomsSystemTeleconferencesTrainingTranslational ResearchTreatment EfficacyTreatment ProtocolsTreatment outcomeUniversitiesUrsidae FamilyValidationWorkalcohol use disorderalternative treatmentbasebrief interventionconditioned feardata integritydata managementexperienceexposed human populationfollow up assessmentfollow-uphuman subjectlearning extinctionmedical schoolsmeetingsmemberneural circuitnovel strategiesoperationpillprogramspsychosocialquality assuranceresponsesocialsuccesssymposiumtreatment programtreatment responsetreatment sitetreatment strategy
项目摘要
DESCRIPTION (provided by applicant): This is a 3-center (PIs: Drs. Otto, Pollack, Tolin) collaborative R01. In this application, we propose to further validate and expand upon one of the apparent striking successes of translational research. Specifically, basic research on the neural circuitry underlying fear extinction led to the examination of d-cycloserine, a partial agonist at the NMDA receptor in the amygdala, as an agent capable of enhancing extinction learning (Davis et al., 2006a; Davis et al., 2006b). Following successful validation of this strategy in the animal laboratory, Ressler et al. (2004) showed that single doses of d-cycloserine (DCS) could enhance extinction in a human exposure paradigm for height phobic adults. This exciting initial finding was replicated by our research team for the treatment of social anxiety disorder in outpatients (Hofmann et al., 2006), and we also have completed a pilot study indicating similar benefits for the treatment of other anxiety disorders. As discussed by Anderson and Insel (2006), these findings have the potential to foster significant advances in the treatment of anxiety disorders. The present study represents the further application of DCS for augmenting the effects of exposure- based cognitive-behavior therapy (CBT), now applied to the treatment of panic disorder with or without agoraphobia. In this application we propose a double-blind randomized controlled trial, conducted at three treatment sites, to compare the relative benefit of augmenting exposure-based CBT with DCS as compared to placebo for patients with panic disorder. In addition, by studying variability at specific gene sites as a predictor of treatment response, particularly for the effects of DCS augmentation, we seek to identify which patients may be particularly responsive to this form of brief, combined treatment. This study capitalizes on the recent successes in translational research to investigate the benefits of the addition of d-cycloserine to a program of brief exposure-based CBT for the treatment of panic disorder with or without agoraphobia. This study addresses an important public health issue by assessing an intervention that may help lead to a more efficient and effective application of empirically-based psychosocial interventions for the treatment of panic disorder and other anxiety disorders. This novel strategy of combining exposure-based treatment and d-cycloserine remains a particularly promising strategy among disappointing alternatives for the treatment of individuals with anxiety disorders, and our research will also provide valuable information on potential genetic moderators of both CBT efficacy as well as d-cycloserine enhancement of this efficacy.
描述(申请人提供):这是一个三中心(PI:博士奥托,波拉克,托林)合作的R01。在这一应用中,我们建议进一步验证和扩展翻译研究的一个明显的显著成功。具体地说,对恐惧消退背后的神经回路的基础研究导致了对d-环丝氨酸的研究,d-环丝氨酸是杏仁核中NMDA受体的一种部分激动剂,能够促进消退学习(Davis等人,2006a;Davis等人,2006b)。在动物实验室成功验证了这一策略后,Ressler等人进行了实验。(2004)表明,在人体暴露模式中,单剂量的d-环丝氨酸(Dcs)可增加恐高症成年人的消光。这一令人兴奋的初步发现被我们的研究团队用于治疗门诊患者的社交焦虑症重复(Hofmann等人,2006年),我们还完成了一项试点研究,表明类似的益处适用于其他焦虑症的治疗。正如Anderson和Insel(2006)所讨论的,这些发现有可能促进焦虑症治疗方面的重大进步。这项研究代表了分布式控制系统的进一步应用,以增强基于暴露的认知行为疗法(CBT)的效果,目前CBT已被应用于治疗伴有或不伴有广场恐怖症的惊恐障碍。在这项申请中,我们提出了一项在三个治疗地点进行的双盲随机对照试验,以比较与安慰剂相比,增加基于暴露的CBT与DCS对惊恐障碍患者的相对好处。此外,通过研究特定基因位点的变异性作为治疗反应的预测因子,特别是对DCs增强的影响,我们试图确定哪些患者可能对这种简短的联合治疗特别有效。这项研究利用最近在翻译研究中取得的成功,调查了在基于短暂暴露的CBT计划中添加d-环丝氨酸的好处,用于治疗伴有或不伴有广场恐怖症的惊恐障碍。这项研究通过评估干预措施,解决了一个重要的公共卫生问题,该干预措施可能有助于更有效地应用基于经验的心理社会干预措施来治疗恐慌症和其他焦虑症。这种基于暴露的治疗和d-环丝氨酸相结合的新策略在治疗焦虑症患者的令人失望的替代方案中仍然是一个特别有希望的策略,我们的研究也将提供关于CBT疗效的潜在遗传调节剂以及d-环丝氨酸增强这一疗效的有价值的信息。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MARK H POLLACK其他文献
MARK H POLLACK的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MARK H POLLACK', 18)}}的其他基金
Dose Timing of D-cycloserine to Augment CBT for Social Anxiety Disorder
D-环丝氨酸增强 CBT 治疗社交焦虑症的剂量时机
- 批准号:
9124959 - 财政年份:2014
- 资助金额:
$ 23.9万 - 项目类别:
Dose Timing of D-cycloserine to Augment CBT for Social Anxiety Disorder
D-环丝氨酸增强 CBT 治疗社交焦虑症的剂量时机
- 批准号:
8700098 - 财政年份:2014
- 资助金额:
$ 23.9万 - 项目类别:
Dose Timing of D-cycloserine to Augment CBT for Social Anxiety Disorder
D-环丝氨酸增强 CBT 治疗社交焦虑症的剂量时机
- 批准号:
8911367 - 财政年份:2014
- 资助金额:
$ 23.9万 - 项目类别:
D-Cycloserine Enhancement of Exposure in Social Phobia
D-环丝氨酸增强社交恐惧症的暴露程度
- 批准号:
8030499 - 财政年份:2010
- 资助金额:
$ 23.9万 - 项目类别:
3/3-Exposure D-Cycloserine Enhancement and Genetic Modulators in Panic Disorder
恐慌症中的 3/3 暴露 D-环丝氨酸增强剂和遗传调节剂
- 批准号:
8279653 - 财政年份:2008
- 资助金额:
$ 23.9万 - 项目类别:
3/3-Exposure D-Cycloserine Enhancement and Genetic Modulators in Panic Disorder
恐慌症中的 3/3 暴露 D-环丝氨酸增强剂和遗传调节剂
- 批准号:
8051529 - 财政年份:2008
- 资助金额:
$ 23.9万 - 项目类别:
3/3-Exposure D-Cycloserine Enhancement and Genetic Modulators in Panic Disorder
恐慌症中的 3/3 暴露 D-环丝氨酸增强剂和遗传调节剂
- 批准号:
7616448 - 财政年份:2008
- 资助金额:
$ 23.9万 - 项目类别:
相似海外基金
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
- 批准号:
MR/Y009568/1 - 财政年份:2024
- 资助金额:
$ 23.9万 - 项目类别:
Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
- 批准号:
10090332 - 财政年份:2024
- 资助金额:
$ 23.9万 - 项目类别:
Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
- 批准号:
MR/X02329X/1 - 财政年份:2024
- 资助金额:
$ 23.9万 - 项目类别:
Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
- 批准号:
MR/X021882/1 - 财政年份:2024
- 资助金额:
$ 23.9万 - 项目类别:
Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
- 批准号:
MR/X029557/1 - 财政年份:2024
- 资助金额:
$ 23.9万 - 项目类别:
Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
- 批准号:
EP/Y003527/1 - 财政年份:2024
- 资助金额:
$ 23.9万 - 项目类别:
Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
- 批准号:
EP/Y030338/1 - 财政年份:2024
- 资助金额:
$ 23.9万 - 项目类别:
Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
- 批准号:
2312694 - 财政年份:2024
- 资助金额:
$ 23.9万 - 项目类别:
Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
- 批准号:
24K19395 - 财政年份:2024
- 资助金额:
$ 23.9万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
- 批准号:
484000 - 财政年份:2023
- 资助金额:
$ 23.9万 - 项目类别:
Operating Grants